SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

22 May 2025 Evaluate
The sales slipped to Rs. 5559.58 millions for the March 2025 quarter as against Rs. 6029.47 millions during the year-ago period.The company reported a drastic decline of -79.54% in the quarter ended March 2025 to Rs. 161.28  millions from Rs. 788.44 millions  .The Operating Profit of the company witnessed a decrease to 800.54 millions from 1370.64 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 5559.58 6029.47 -7.79 21394.23 18661.17 14.65 21394.23 18661.17 14.65
Other Income 121.22 256.47 -52.74 461.88 587.11 -21.33 461.88 587.11 -21.33
PBIDT 800.54 1370.64 -41.59 3086.30 2092.16 47.52 3086.30 2092.16 47.52
Interest 293.60 390.50 -24.81 1459.12 1393.77 4.69 1459.12 1393.77 4.69
PBDT 506.94 979.40 -48.24 1626.91 644.74 152.34 1626.91 644.74 152.34
Depreciation 223.71 219.24 2.04 846.08 874.07 -3.20 846.08 874.07 -3.20
PBT 283.23 760.16 -62.74 780.83 -229.33 -440.48 780.83 -229.33 -440.48
TAX 121.95 -28.28 -531.22 189.27 13.42 1310.36 189.27 13.42 1310.36
Deferred Tax 174.31 -1.26 -13934.13 203.91 14.61 1295.69 203.91 14.61 1295.69
PAT 161.28 788.44 -79.54 591.56 -242.75 -343.69 591.56 -242.75 -343.69
Equity 921.63 919.00 0.29 921.63 919.00 0.29 921.63 919.00 0.29
PBIDTM(%) 14.40 22.73 -36.66 14.43 11.21 28.67 14.43 11.21 28.67

Strides Pharma Scien Share Price

995.90 -4.80 (-0.48%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×